Loading
A phase 1/2 trial of Eflornithine, Fulvestrant, Capivasertib in melanoma and skin cancer, run by Aminex Therapeutics, Inc., now recruiting.
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07287917 by Aminex Therapeutics, Inc., with 92 participants planned, started 2026-01-26 and due to reach its primary completion in 2028-02-28. Interventions recorded: AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab. Conditions listed: Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer. No results are recorded here; the registry entry is the source.
Shares Capivasertib, Fulvestrant.
Shares Capivasertib, Fulvestrant.
Shares Capivasertib, Fulvestrant.
Shares Capivasertib, Fulvestrant.
Shares Capivasertib, Fulvestrant.
Shares Capivasertib, Fulvestrant.
Shares Capivasertib, Fulvestrant.
Shares Capivasertib, Fulvestrant.